These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10342639)

  • 1. Normotensive renal failure in a patient with systemic sclerosis and p-antineutrophil cytoplasmic autoantibodies which developed into Paget's disease of bone after immunosuppressive therapy.
    Villaverde V; Balsa A; Cabezas JA; Fernández-Prada M; Torre A; Mola EM
    Rheumatology (Oxford); 1999 Feb; 38(2):190-1. PubMed ID: 10342639
    [No Abstract]   [Full Text] [Related]  

  • 2. Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies.
    Hillis GS; Khan IH; Simpson JG; Rees AJ
    Am J Kidney Dis; 1997 Aug; 30(2):279-81. PubMed ID: 9261042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antineutrophil cytoplasmic autoantibodies (ANCA) and systemic sclerosis.
    Carvajal I; Bernis C; Sanz P; Garcia A; Garcia-Vadillo A; Traver JA
    Nephrol Dial Transplant; 1997 Mar; 12(3):576-7. PubMed ID: 9075145
    [No Abstract]   [Full Text] [Related]  

  • 4. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis.
    Endo H; Hosono T; Kondo H
    J Rheumatol; 1994 May; 21(5):864-70. PubMed ID: 8064727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antineutrophil cytoplasmic autoantibodies in systemic sclerosis with renal failure.
    Huong DL; Papo T; Gatfosse M; Frances C; Godeau P; Beaufils H
    J Rheumatol; 1995 Apr; 22(4):791-2. PubMed ID: 7791189
    [No Abstract]   [Full Text] [Related]  

  • 6. Antineutrophil cytoplasmic antibodies a "Red Flag" in patients with systemic sclerosis.
    Casari S; Haeney M; Farrand S; Herrick A
    J Rheumatol; 2002 Dec; 29(12):2666-7. PubMed ID: 12465176
    [No Abstract]   [Full Text] [Related]  

  • 7. Scleroderma associated with ANCA-associated vasculitis.
    Rho YH; Choi SJ; Lee YH; Ji JD; Song GG
    Rheumatol Int; 2006 Mar; 26(5):465-8. PubMed ID: 16012875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure.
    Katrib A; Sturgess A; Bertouch JV
    Rheumatol Int; 1999; 19(1-2):61-3. PubMed ID: 10651085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scleroderma with type III glomerulonephritis and MPO-ANCA antibodies in the serum.
    Herrera-Esparza R; Aguilar JL; Saucedo A; González I; López-Robles E; Avalos-Díaz E
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):617-20. PubMed ID: 16164722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of antineutrophil cytoplasmic antibodies in Algerian scleroderma patients.
    Tahiat A; Djidjik R; Abdessmed A; Mellal Y; Nebbab A; Gharnaout M; Ghaffor M; Ladjouze A
    Joint Bone Spine; 2013 Oct; 80(5):547-8. PubMed ID: 23541846
    [No Abstract]   [Full Text] [Related]  

  • 11. Antineutrophil cytoplasmic antibodies in patients with systemic sclerosis.
    Manolova I; Dancheva M
    J Rheumatol; 2003 Sep; 30(9):2078-9; author reply 2079-80. PubMed ID: 12966621
    [No Abstract]   [Full Text] [Related]  

  • 12. Antineutrophil cytoplasmic antibodies in systemic sclerosis.
    Kiraz S; Simsek H; Ertenli I; Benekli M; Kadayifci A
    Clin Rheumatol; 1996 Sep; 15(5):519-20. PubMed ID: 8894374
    [No Abstract]   [Full Text] [Related]  

  • 13. [Progressive systemic sclerosis associated with anti-myeloperoxidase ANCA vasculitis with renal and cutaneous involvement].
    Martínez Ara J; Picazo ML; Torre A; Pascual D; Díaz Rodríguez C; Riñón C
    Nefrologia; 2000; 20(4):383-6. PubMed ID: 11039266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis.
    Akimoto S; Ishikawa O; Tamura T; Miyachi Y
    Br J Dermatol; 1996 Mar; 134(3):407-10. PubMed ID: 8731661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is "resistance" in Paget's disease of bone?
    Lyles KW
    Arthritis Rheum; 2003 Aug; 48(8):2097-9. PubMed ID: 12905461
    [No Abstract]   [Full Text] [Related]  

  • 16. Paget's disease 1: epidemiology, causes and clinical features.
    Sutcliffe A
    Nurs Times; 2009 Feb 17-23; 105(6):14-5. PubMed ID: 19271575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with systemic sclerosis, severe cytopenias and the simultaneous presence of anti-centromere and anti-SCL-70-antibodies.
    Hietarinta M; Tertti R; Lassila O
    Clin Exp Rheumatol; 1993; 11(4):457-8. PubMed ID: 8403594
    [No Abstract]   [Full Text] [Related]  

  • 18. Autoantibodies to bactericidal/permeability-increasing protein and cathepsin G in systemic sclerosis.
    Grypiotis P; Cozzi F; Ruffatti A
    J Rheumatol; 2004 Jul; 31(7):1468-9. PubMed ID: 15229985
    [No Abstract]   [Full Text] [Related]  

  • 19. [Association of Thibierge-Weissenbach type scleroderma with Paget's disease].
    Commandré FA; Bonnefond O; Berato J; Mattei P; Laurie M
    Rhumatologie; 1967 May; 19(5):179-85. PubMed ID: 5620140
    [No Abstract]   [Full Text] [Related]  

  • 20. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis.
    Khanna D; Aggarwal A; Bhakuni DS; Dayal R; Misra R
    J Rheumatol; 2003 Jun; 30(6):1248-52. PubMed ID: 12784398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.